Yu-Ying Tsai

USPTO Granted Patents = 7 (Patent Applications = 8)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 50(Granted Patents)

Company Filing History:

Taiwan Semiconductor Manufacturing Comp. Ltd.

patents

2 out of 5

Abgenomics International Inc.

patents

where one patent can have more than one assignee

Years Active: 2005-2019

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10472422 - Tetravalent anti-PSGL-1 antibodies and uses thereof (2019-11-12),

2. 9950077 - Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof (2018-04-24),

3. 9334329 - Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same (2016-05-10),

4. 8568718 - Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same (2013-10-29),

5. 7982017 - Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same (2011-07-19),

6. 7884471 - Solder bump and related intermediate structure having primary and secondary portions and method of manufacturing same (2011-02-08),

7. 6977213 - IC chip solder bump structure and method of manufacturing same (2005-12-20),

Title: **Innovator Yu-Ying Tsai: A Pioneer in Antibody Therapeutics**

Introduction

Yu-Ying Tsai, an accomplished inventor based in Taipei, Taiwan, has made significant contributions to the field of biomedical science, particularly in the development of innovative antibody technologies. With a portfolio of seven patents, his inventions are at the forefront of addressing critical medical challenges.

Latest Patents

Among his notable patents are the "Tetravalent anti-PSGL-1 antibodies and uses thereof," which introduces a novel format of tetravalent antibodies specifically designed to bind human PSGL-1. This advancement allows for enhanced efficacy in targeting cellular processes involved in T-cell mediated inflammatory diseases and transplantation. His second significant patent, "Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof," focuses on a hydrophilic self-immolative linker for antibody-drug conjugates aimed at cancer treatment. These patents underscore his commitment to developing therapeutic solutions for complex health issues.

Career Highlights

Yu-Ying Tsai has built a robust career in the biopharmaceutical sector, working with distinguished companies such as BioAlliance S.A. and Taiwan Semiconductor Manufacturing Company Limited. His experience in these organizations has played a vital role in honing his skills as an inventor and scientist, particularly in the realm of therapeutic antibodies.

Collaborations

Throughout his career, Yu-Ying has collaborated with talented individuals such as Shih-Yao Lin and Leewen Lin. These partnerships have been instrumental in the advancement of his research and the successful development of his innovative patents.

Conclusion

In summary, Yu-Ying Tsai's work is characterized by pioneering inventions that have the potential to revolutionize treatments for various diseases. His dedication to innovation and collaborative spirit continues to inspire advancements in biomedical research, with lasting impacts on healthcare.

This text is generated by artificial intelligence and may not be accurate.